Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi)

TNF blockers suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases, such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The drugs in this class include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab).

This information reflects FDA’s current analysis of data available to FDA concerning this drug. FDA intends to update this sheet when additional information or analyses become available.

To report any unexpected adverse or serious events associated with the use of these drugs, please contact the FDA MedWatch program using the information at the bottom of this page.

Related Information

- FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria (/Drugs/DrugSafety/ucm270849.htm) 9/7/2011
- FDA Drug Safety Communication: Safety Review update on reports of Hepatosplenic T-Cell Lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine (/Drugs/DrugSafety/ucm250913.htm) 4/14/2011
- FDA ALERT [9/4/2008]
Labeling and Regulatory History from Drugs@FDA

- **Certolizumab Pegol** (marketed as Cimzia) Prescribing and Labeling Information
  (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?
  fuseaction=Search.SearchAction&searchTerm=cimzia&SearchType=BasicSearch)

- **Etanercept** (marketed as Enbrel) Prescribing and Labeling Information
  (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?
  fuseaction=Search.SearchAction&searchTerm=enbrel&SearchType=BasicSearch)

- **Adalimumab** (marketed as Humira) Prescribing and Labeling Information
  (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?
  fuseaction=Search.SearchAction&searchTerm=humira&SearchType=BasicSearch)

- **Infliximab** (marketed as Remicade) Prescribing and Labeling Information
  (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?
  fuseaction=Search.SearchAction&searchTerm=remicade&SearchType=BasicSearch)

- **Golimumab** (marketed as Simponi) Prescribing and Labeling Information
  (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?
  fuseaction=Search.SearchAction&searchTerm=simponi&SearchType=BasicSearch)

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax

Report a Serious Problem

MedWatch Online (https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm)


Mail to: MedWatch 5600 Fishers Lane
Rockville, MD 20857

More in Postmarket Drug Safety Information for Patients and Providers

(/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/default.htm)

Index to Drug-Specific Information (/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111085.htm)